Express Pharma

DRL in pact with Gland Pharma in the US market


To market and distribute a diverse portfolio of eight injectable ANDAs

Dr Reddy’s Laboratories (DRL) has entered into a strategic collaboration with Gland Pharma, to market and distribute a diverse portfolio of eight injectable Abbreviated New Drug Applications (ANDAs). The portfolio is a mix of filed ANDAs pending approval by the US Food and Drug Administration (US FDA) and ANDAs that will be filed imminently, and comprised of generic injectables administered in hospitals and clinics in the US. The combined sale of branded and generic versions of the products in the US is approximately $1 billion MAT for the most recent twelve months ending in August 2016 according to IMS Health.

Alok Sonig, Executive VP and Head of North America, DRL said, “We are excited about this opportunity. DRL has a strong track record in developing, marketing and distributing generic injectables in the US. Our strengths, combined with Gland’s track record of manufacturing and operational excellence, will help bring affordable medications within reach of patients and complement our specialty injectables offering in the short-to-medium term.”

Srinivas Sadu, COO, Gland Pharma added, “We are happy to expand our collaboration with DRL for marketing and distribution of Gland Products in US and other Ex US markets. DRL has an impressive track record of commercialising injectables products in the US, and we are confident that our partnership will continue to grow.”

EP News Bureau

Comments are closed.